Fig. 11From: Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancerTMB and TIDE in diferent risk groups. A The tumor mutation burden outcomes of patients in the high-low mutation group; B Comparison of Tumor immune escape scores in two risk groups (***P < 0.001)Back to article page